FOI release

hospitalisations linked to GLP-1 drugs

Some or all of the information requested was not provided because we determined that the cost to do so would exceed the appropriate limit.

Case reference FOI2025/00296

Received 25 March 2025

Published 30 May 2025

Request

Please confirm the total number of suspected reactions in association with GLP-1 receptor agonists indicated (used) for weight management only (NB: please do not include hospitalisations where the indication includes diabetes). Please confirm how many of these suspected reactions reported the hospitalisation of the individual. In addition, please supply details of the ten most common suspected reactions which led to the hospitalisations. How many reports has the MHRA received of pulmonary aspiration during surgical procedures in patients receiving GLP-1 drugs for any indication?

Response

see attached

Documents

• FOI2025_00296 redacted for publication.pdf (100.5 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.